Pilot study of multiagent chemotherapy with intrathecal chemotherapy and delayed local radiotherapy in patients with atypical teratoid/rhabdoid tumors.

Pilot study of multiagent chemotherapy with intrathecal chemotherapy and delayed local radiotherapy in patients with atypical teratoid/rhabdoid tumors. - Multiagent chemotherapy with intrathecal chemotherapy and delayed local radiotherapy for atypical teratoid/rhabdoid tumors.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014490

Enrollment

Registered

2014-08-01

Start date

2014-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atypical teratoid/rhabdoid tumor

Interventions

Operation, multiagent chemotherapy (vincristine, pirarubicin, etoposide, cyclophosphamide, cisplatin, carboplatin, methotrexate, ifosfamide, actinomycin-D, melphalan), and radiotherapy (54Gy).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of 1 of the following, atypical teratoid/rhabdoid tumor, INI-1 negative choroid plexus carcinoma. 2. Has undergone operation within the past 42 days. 3. No prior radiotherapy. 4. None or one course of prior chemotherapy. 5. PS score: 0-3. 6. WBC >2000/mm3, ANC >1000/mm3, Platelet count >100000/mm3, ALT <100 IU/L, T-bil <1.5 mg/dl, serum creatinine < upper limit of normal.

Exclusion criteria

Exclusion criteria: 1. Has double cancer. 2. Has cardiac disease for which treatment is necessary. 3. Pregnant or nursing.

Design outcomes

Primary

Measure	Time frame
Rates of adverse events and early treatment failure.	—

Countries

Japan

Contacts

Public ContactKeiko Okada

Osaka City General Hospital Pediatric Hematology/Oncology

keik-okada@hospital.city.osaka.jp+81-6-6929-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026